Search Results
Your search for ,Any matches 8112 pages
Showing 751 - 800Two Adjuvant Therapy Studies Show Divergent Outcomes With PD-1 Inhibitors in Renal Cell Carcinoma
In the third prespecified interim analysis of the phase III KEYNOTE-564 trial,1 adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved overall survival compared with placebo in patients with intermediate- or high-risk clear cell renal cell carcinoma (RCC). However, a...
Esophageal Squamous Cell Cancer: Overall Survival Improved With Tiragolumab and Atezolizumab Plus Chemotherapy
For patients with treatment-naive, locally advanced or metastatic esophageal squamous cell carcinoma, the addition of two checkpoint inhibitors to chemotherapy significantly improved not only progression-free survival but also overall survival, in the randomized, phase III SKYSCRAPER-08 trial...
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
On March 6, the U.S. Food and Drug Administration (FDA) approved the CD22-targeted antibody-drug conjugate inotuzumab ozogamicin (Besponsa) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Study WI203581...
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and Other Cancers
The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for...
Online Genetic Education Programs May Spur Testing for Patients at Risk for Cancer
Researchers have demonstrated that an online genetic education program may encourage patients with a family history of cancer to undertake genetic testing, according to a recent study published by Rodriguez et al in Gastroenterology. Background Although research has shown that an inherited...
President’s Cancer Panel Report Highlights Opportunities to Accelerate Progress Toward the National Cancer Plan
A new report from the President’s Cancer Panel offers recommendations in five priority areas to accelerate progress toward implementing the National Cancer Plan and achieving the Biden-Harris Administration’s Cancer Moonshot goal of ending cancer as we know it. The report, delivered to President...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Belzutifan: New Standard in Previously Treated Renal Cell Carcinoma
Belzutifan is a first-in-class, oral hypoxia-inducible factor (HIF)-2α inhibitor, and active HIF-2α is a key oncogenic driver in clear cell renal cancer. The manufacturer has filed a new drug application for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and...
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
First-Line Radioligand-Based Therapy Demonstrates Benefit in Some Neuroendocrine Tumors
Adding the radioligand lutetium-177 dotatate (Lu-177 dotatate) to standard therapy almost tripled the median progression-free survival in patients with untreated, high-grade, gastroenteropancreatic neuroendocrine tumors in the randomized phase III NETTER-2 study, researchers reported at the 2024...
Postdiagnosis Mental Disorders Among AYAs With Cancer
In a Canadian study reported in the Journal of Clinical Oncology, Oberoi et al found that adolescents and young adults (AYAs) with cancer were at an increased risk of mental disorders compared with cancer-free matched population-based and sibling cohorts. Study Details The retrospective...
Strategies to Reduce Burden of Colorectal Cancer in Latin America
Investigators may have identified colorectal cancer screening programs in Latin America, according to a recent systematic review and meta-analysis published by Montalvan-Sanchez et al in JAMA Network Open. Background Colorectal cancer—the second leading cause of cancer-related mortality...
Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...
Genetic Alterations Associated With Interval Breast Cancer Diagnosis
In a Swedish study reported in JAMA Oncology, Rodriguez et al identified characteristics of interval breast cancers—those diagnosed between two screening examinations—compared with screen-detected cancers on the basis of analysis of rare germline genetic deleterious protein-truncating variants. As...
Modified Chemotherapy Regimens May Improve Quality of Life in Older Patients With Advanced Cancer
Reducing doses and adjusting chemotherapy schedules in older patients with advanced cancer may help improve treatment tolerability without compromising its efficacy, according to a recent study published by Mohamed et al in JAMA Network Open. Background Standard chemotherapy regimens—mostly based...
Ablative Stereotactic Magnetic Resonance–Guided Adaptive Radiation Therapy for Pancreatic Ductal Adenocarcinoma
Researchers have found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control and overall survival in patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma, according to a recent study published by Chuong et ...
First-Line Ruxolitinib Combinations Boost Benefit Over Single Agent in Myelofibrosis
In two international phase III trials in myelofibrosis, drugs given in combination with the Janus kinase (JAK) inhibitor ruxolitinib in JAK inhibitor–naive patients significantly improved outcomes vs ruxolitinib alone. Both studies were presented at the 2023 American Society of Hematology Annual...
Study Finds Four-Drug Targeted Treatment Reduces Chemotherapy Requirement for Some in Large B-Cell Lymphoma
A four-drug targeted therapy regimen proved safe and effective as the first-line treatment of diffuse large B-cell lymphoma (DLBCL), achieving a 100% response rate after four cycles, researchers from The University of Texas MD Anderson Cancer Center, Houston, reported at the 2023 American Society...
‘Ultra-Low Dose’ of Radiotherapy May Be Enough in Gastric MALT Lymphoma, Study Finds
For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...
PEGasparaginase Dosing and Risk of Hypersensitivity Reactions in Pediatric ALL
In a Dutch study reported in the Journal of Clinical Oncology, van der Sluis et al found that continuous dosing of PEGasparaginase was associated with a significantly reduced incidence of hypersensitivity reactions vs standard noncontinuous dosing in newly diagnosed pediatric patients with...
Addition of Isatuximab to Carfilzomib-Based Regimen Doubles MRD Negativity Rates in Multiple Myeloma
In the phase III IsKia trial in newly diagnosed multiple myeloma, therapy incorporating the CD38-directed monoclonal antibody isatuximab-irfc with a carfilzomib-based regimen led to high rates of minimal residual disease (MRD) negativity at postconsolidation cutoffs, as reported at the 2023...
Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online
Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...
Plant-Based Diet May Be Linked to Improved Sexual Health in Men Treated for Prostate Cancer
Plant-based diets may be linked to a lower risk of erectile dysfunction, urinary incontinence, and other common side effects experienced by patients receiving treatment for prostate cancer, according to a new study published by Loeb et al in Cancer. The findings indicated that nutrition may lead to ...
Shedding Light on Mechanisms Behind Fulvestrant Resistance in Advanced ER-Positive Breast Cancer
Researchers may have uncovered the factors contributing to hormone therapy resistance in some patients with advanced estrogen receptor (ER)-positive breast cancer, according to a recent study published by Kingston et al in Cancer Discovery. The findings may indicate drugs currently in development...
Are Major Adverse Financial Events Linked to a Later-Stage Cancer Diagnosis?
Studies have shown that millions of people in the United States are financially vulnerable because of low income, limited savings, or high levels of debt. In 2021, 32% of U.S. adults reported being unable to cover an unexpected expense of $400. A recent study by researchers at the American Cancer...
EBV-Positive Posttransplantation Lymphoproliferative Disease: T-Cell Immunotherapy Efficacy
In the phase III ALLELE trial reported in The Lancet Oncology, Mahadeo et al found that the Epstein-Barr virus (EBV)-specific T-cell immunotherapy tabelecleucel produced high response rates—and few of the toxicities associated with other adoptive T-cell therapies—in allogeneic hematopoietic stem...
How ASCO’s Regional Councils Are Having an International Impact on Patients With Cancer
In September 2023, ASCO announced the establishment of its fourth regional council, the Central and Eastern European Regional Council, which includes representatives from 17 countries, with the goal of expanding ASCO’s mission globally to “conquer cancer through research, education, and promotion...
Intensification of ADT in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer After Radical Prostatectomy
As reported in the Journal of Clinical Oncology by Aggarwal et al, interim analysis of the phase III PRESTO trial showed that the addition of apalutamide as well as the addition of apalutamide plus abiraterone acetate/prednisone (AAP) to androgen-deprivation therapy (ADT) improved prostate-specific ...
Global Cancer Burden May Be Growing Amidst Mounting Need for Cancer Services
The World Health Organization’s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has released updated findings of the current global burden of cancer alongside World Cancer Day on February 4, 2023. The WHO indicated that a majority of countries do not adequately finance...
Actinium-225–PSMA Radioligand Therapy for Prostate Cancer
In a retrospective study (WARMTH Act) reported in The Lancet Oncology, Sathekge et al found that actinium-225–prostate-specific membrane antigen (PSMA) radioligand therapy showed activity in patients with metastatic castration-resistant prostate cancer. Study Details The study consisted of 448...
Survivors of Childhood Cancer With High Anthracycline Exposure: Can a Beta-Blocker Improve Cardiac Function?
In a U.S./Canadian phase IIb trial (PREVENT-HF) reported in The Lancet Oncology, Armenian et al found that the beta-blocker carvedilol did not significantly improve cardiac function—measured as standardized left ventricular wall thickness–dimension ratio Z score (LVWT/Dz)—vs placebo in survivors of ...
Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies
In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best...
Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...
Reframing DCIS as an Opportunity for Cancer Prevention
We have been taught that early cancer detection and treatment save lives. The way to cure cancer is to find it early and treat it aggressively. The public has subscribed to this approach in our struggle to “eradicate cancer.” In certain disease types, there is merit to this philosophy. The ability...
Adjuvant Treatment of Resected Melanoma: mRNA-Based Personalized Therapy Plus Immunotherapy
In the phase IIb KEYNOTE-942 trial reported in The Lancet, Jeffrey S. Weber, MD, PhD, and colleagues found that the addition of adjuvant mRNA-4157—a novel mRNA-based individualized neoantigen therapy—to pembrolizumab numerically improved recurrence-free survival in patients with completely resected ...
Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC
In a U.S. single-center radiation dose-expansion study reported in JAMA Oncology, Wu et al found that chemoradiation with adaptively increased stereotactic ablative radiotherapy (SABR) boost doses was safe and effective in patients with locally advanced, unresectable non–small cell lung cancer...
Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas
In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas. Study Details The study included 24 patients with...
More Intensified Salvage Regimen for Prostate Cancer Does Not Impair Health-Related Quality of Life
In patients with biochemically recurrent prostate cancer after radical prostatectomy, a more intensified regimen of abiraterone acetate/prednisone plus apalutamide improved outcomes and did not lead to decrements in specific domains of health-related quality of life (HRQoL) vs treatment with...
Survival Benefit With Adjuvant Immunotherapy in Patients With Clear Cell RCC
The phase III KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma at high risk of recurrence after surgery. This study is significant, as it represents the first phase III study to show...
Secondary Cancers May Be Rare in Patients Treated With CAR T-Cell Therapy
The development of any type of secondary cancer following chimeric antigen receptor (CAR) T-cell therapy may be rare, according to a recent study published by Ghilardi et al in Nature Medicine. Background Secondary cancers, including T-cell lymphomas, are known risks of cancer treatments such as...
Intensified vs Standard Induction in Younger Patients With Newly Diagnosed AML
In a UK trial (NCRI AML19) reported in the Journal of Clinical Oncology, Russell et al found that intensified induction therapy with FLAG-Ida (fludarabine, cytarabine, granulocyte colony–stimulating factor, and idarubicin) plus gemtuzumab ozogamicin did not improve overall survival in younger...
Generic Drug Shortages and Essential Cancer Medicines
Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cancer settings that treat both well-off and socioeconomically disadvantaged patients. However, these...
NATALEE Trial: Long-Term Results on Ribociclib Combination Therapy in Early-Stage Breast Cancer
Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone....
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
Gemcitabine/Paclitaxel vs Gemcitabine Alone After FOLFIRINOX in Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by De La Fouchardière et al, the French phase III GEMPAX trial showed no overall survival benefit with second-line gemcitabine/paclitaxel vs gemcitabine alone after FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) in patients with metastatic...
My Breast Cancer Experience Has Led Me to Leverage My Expertise in Human-Centered Design to Transform Patient Care
The road to my breast cancer diagnosis in 2018 was long and tortuous. For 3 years leading up to the diagnosis, I had imaging scans and tissue biopsies every 3 months because of suspicious masses in my breasts. The uncertainty was so destabilizing that I was in a constant state of emotional unrest....
Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
